Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787926 | 0.81 | KDM4E (0.32) | ALDH1A1SMN1; SMN2AR | |
| SCHEMBL6788379 | 0.80 | TSHR (0.34) | ALDH1A1SMN1; SMN2MAPTAR | |
| SCHEMBL6785783 | 0.76 | ABL1 (0.30) | — | |
| SCHEMBL7460345 | 0.73 | TSHR (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7463770 | 0.68 | POLB (0.37) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28291726 | 0.67 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7454862 | 0.67 | SLC13A5 (0.30) | — | |
| SCHEMBL7468653 | 0.65 | — | — | |
| SCHEMBL6786070 | 0.65 | BRD4 (0.36) | ALDH1A1SMN1; SMN2BRD4AR | |
| SCHEMBL6785950 | 0.64 | NUDT1 (0.36) | ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699876-B2 | FOR CANCER THERAPY | LES LABORATOIRES SERVIER (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20030105109-A1 | For cancer therapy | LES LABORATOIRES SERVIER (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6509345-B2 | For therapy of cancerous diseases | LES LABORATOIRES SERVIER (FR) | 2003-01-21 | — | — | US | disclosed |
| US-20020077325-A1 | New camptothecin analogue compounds | LAVIELLE GILBERT (FR) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105109-A1 | For cancer therapy | OXER1, OXGR1, CBR1 | ALDH1A1 571/4885SMN1; SMN2 3240/4885MAPT 4776/4885 |
| US-20020077325-A1 | New camptothecin analogue compounds | OXER1, CBR3, CBR1 | ALDH1A1 1458/4885SMN1; SMN2 4239/4885MAPT 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.